05-348 | Anti-Tau Antibody, clone 5E2

05-348
200 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      B, H, M, R, RbWB, IHCMPurifiedMonoclonal Antibody
      Description
      Catalogue Number05-348
      ReplacesMAB10417
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-Tau Antibody, clone 5E2
      References
      Product Information
      FormatPurified
      Presentation0.1M Tris-glycine, pH 7.4, containing and 0.05% sodium azide
      Applications
      ApplicationDetect Tau using this Anti-Tau Antibody, clone 5E2 validated for use in WB, IH.
      Key Applications
      • Western Blotting
      • Immunohistochemistry
      Biological Information
      ImmunogenFetal heat stable MAPS
      Cloneclone 5E2
      HostMouse
      Specificityseveral parts of Tau protein between 50kDa and 70kDa
      IsotypeIgG1
      Species Reactivity
      • Bovine
      • Human
      • Mouse
      • Rat
      • Rabbit
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
      Gene Symbol
      • MAPT
      • MTBT2
      • tau
      • FTDP-17
      • MSTD
      • TAU
      • MTBT1
      • PHF-tau
      • MGC138549
      • MAPTL
      • FLJ31424
      • DDPAC
      • PPND
      Purification MethodProtein G Chromatography
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
      SIZE: 758 amino acids; 78878 Da
      SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
      SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
      TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
      DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
      PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
      DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
      SIMILARITY: Contains 4 Tau/MAP repeats.
      Molecular Weight50-70kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated in immunoblot on rat brain preparations
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage Conditions2 years at -20°C
      Packaging Information
      Material Size200 µg
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SDS

      Title

      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) - 2436378 2436378
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) 2828579
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) -
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) - 1972313 1972313
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) - 2032276 2032276
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) - 2344636 2344636
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) - DAM1498597 DAM1498597
      Anti-Tau, clone 5E2 (mouse monoclonal IgG1) -2495645 2495645
      Anti-Tau, clone 5E2 - 14227 14227
      Anti-Tau, clone 5E2 - 2563499 2563499

      References

      Reference overviewApplicationPub Med ID
      CRMP-2 binds to tubulin heterodimers to promote microtubule assembly
      Fukata, Y., et al
      Nat Cell Biol, 4:583-91 (2002)  2002

      Immunoblotting (Western)12134159 12134159
      Morphometric image analysis of neuropil threads in Alzheimer's disease.
      Markesbery, W R, et al.
      Neurobiol. Aging, 14: 303-7 (1993)  1993

      Show Abstract
      8367011 8367011
      Microtubular reorganization and dendritic growth response in Alzheimer's disease.
      McKee, A C, et al.
      Ann. Neurol., 26: 652-9 (1989)  1989

      Show Abstract
      2817839 2817839
      Epitopes that span the tau molecule are shared with paired helical filaments.
      Kosik, K S, et al.
      Neuron, 1: 817-25 (1988)  1988

      Show Abstract
      2483104 2483104
      Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease.
      Kowall, N W and Kosik, K S
      Ann. Neurol., 22: 639-43 (1987)  1987

      Show Abstract
      3122646 3122646
      Tau epitopes are incorporated into a range of lesions in Alzheimer's disease.
      Joachim, C L, et al.
      J. Neuropathol. Exp. Neurol., 46: 611-22 (1987)  1987

      Show Abstract
      2443617 2443617
      MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum.
      Kosik, K S and Finch, E A
      J. Neurosci., 7: 3142-53 (1987)  1987

      Show Abstract
      2444675 2444675

      FAQ

      QuestionAnswer
      I would like to use this monoclonal antibody on mouse tissue, are there any special procedures I should follow?To reduce the background interaction between the monoclonal antibody and the mouse tissue, you will need to perform antigen retrieval and use a special secondary antibody. For antigen retrieval, prepare a citrate buffer by mixing 19ml of 0.1M citric acid and 82ml of 0.1M sodium citrate to make 1000ml of buffer. Adjust the pH to 6.0 before each use. Add buffer to your slide. Using an 800 watt microwave oven with rotation, microwave for 7.5 min at high, 5 min at 50% (3 cycles), checking the slide at the end of each cycle to see if the solution needs to be replaced, adding water if needed. For the secondary antibody, use a biotinylated isotype specific secondary IGG (IGG-1) and a 3% donkey serum block. This will help reduce the background issues using mouse monoclonals.

      Related Products & Applications

      Alternative Packsize

      Catalogue Number Description  
      05-348-KC Anti-Tau, clone 5E2 (KC) Show Pricing & Availability

      Product Families

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies